CommercialPrior AuthMedium impact
Hemophilia Therapies
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Pediatrics, Internal Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield Mississippi updated their hemophilia therapies medical policy requiring prior authorization for all Factor VIII and Factor IX therapies. The policy establishes detailed documentation requirements including treatment logs, patient dosing information, and specific criteria for long-acting products.
Action Required
Immediately: Billing team must ensure prior authorization is obtained for all hemophilia therapies (Factor VIII and Factor IX products) before treatment. Providers must maintain detailed treatment logs including date/time of bleeds, location/severity, treatment used with brand name/lot number/units administered, and submit copies for renewals. Update prior auth request forms to include patient age, weight, factor deficiency severity, activity level, bleed history, trough levels, and inhibitor status.